
FDA Approves Losartan Potassium for Reduction in Risk of Stroke
The FDA approved losartan potassium (Arbli) as an oral suspension 10 mg/mL for the reduction in risk of stroke for patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy for some patients with type 2 …